DSI
CRSP icon

Daiwa SB Investments’s CRISPR Therapeutics CRSP Stock Holding History

Daiwa SB Investments’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,800
Closed -$61K – 249
2017
Q1 		$61K Buy
+2,800
New +$55K 0.02% 177

Other funds holding CRSP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Daiwa SB Investments's CRSP Position: Q2 2017 in Review

Daiwa SB Investments sold out of CRISPR Therapeutics (CRSP) in Q2 2017, closing a stake of 2,800 shares — an estimated $61K sold.

Daiwa SB Investments first reported a position in CRSP in Q1 2017 and held it in 1 quarter. The position peaked at $61K in Q1 2017. 39 funds tracked by Wall St. Rank hold CRSP as of Q2 2017.

  • Daiwa SB Investments reported no remaining CRISPR Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Daiwa SB Investments sold 2,800 CRISPR Therapeutics shares in Q2 2017, an estimated $61K.
  • Daiwa SB Investments first reported a position in CRISPR Therapeutics in Q1 2017 and held it in 1 quarter.
  • Daiwa SB Investments's CRISPR Therapeutics position peaked at $61K in Q1 2017.
  • 39 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2017.

Based on Daiwa SB Investments's 13F filing for Q2 2017, filed 11 Jul 2017.